Tải xuống
Tóm tắt
Background: Extranodal NK/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma, origin from natural killer (NK) cells and T cells. This is a rare, fast-growing and poor prognosis disease. Currently there have been not many studies in Vietnam on this issue. We conduct this research with two objects: to describe characteristics of patients and evaluate premininary results of treatment extranodal NK/T cell lymphoma, nasal type, stage I to II at K hospital.
Methods: Retrospective study. From January 2017 to June 2020, we enrolled 26 patients with extranodal NK/T cell lymphoma, nasal type, stage I to II. Patients were treated concurrent chemoradiotherapy with cisplatin, followed by 3 cycles of VIPD adjuvant regimen.
Results: Patient characteristics: The average age was 43.2. Male/female ratio was 1.36. The most common symptoms were stuffy of nose 84.6%; runny nose 65.4%. Peripheral lymph nodes observed in 19.2%; 50% with B symptom. Staged I was dominated with 73.1%. Treatment results: Concurrent chemoradiotherapy phase: completed response was 26.9%, partial response 53.8% and progression disease 19.2%. At the end of treatment course, the overall response rate was 73% (including 61.5% completed response and 11.5% partial response), 26.9% cases with disease progression. Toxicity: Leukopenia was the most common toxicity (61.1%). Grade III and IV leukopenia were observed in 18.4%.
Conclusions: Concurrent chemoradiotherapy followed by adjuvant VIPD regimen with stage I, II is effective regimen and acceptable toxicity.
Tài liệu tham khảo
Campo E., Swerdlow S.H., Harris N.L., et al. (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117(19), 5019-5032.
Wing Y. Au M.D. (2010). Current Management of Nasal NK/T-cell Lymphoma. Cancer Network, <https://www.cancernetwork.com/review-article/current-management-nasal-nktcell-lymphoma>, accessed: 06/16/2019.
Vose J., Armitage J., Weisenburger D., et al. (2008). International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol Off J Am Soc Clin Oncol, 26(25), 4124-4130.
Koom W.S., Chung E.J., Yang W.-I., et al. (2004). Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol • Biol • Phys, 59(4), 1127-1137.
Li Y.-X., Yao B., Jin J., et al. (2006). Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma. J Clin Oncol, 24(1), 181-189.
Kim S.J., Kim K., Kim B.S., et al. (2009). Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol Off J Am Soc Clin Oncol, 27(35), 6027-6032.
Au W., Weisenburger D.D., Intragumtornchai T., et al. (2009). Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood, 113(17), 3931-3937.
Li Y.-X., Liu Q.-F., Fang H., et al. (2009). Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma. Clin Cancer Res, 15(8), 2905-2912.
| Đã xuất bản | 05-01-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 64 (2020) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.38103/jcmhch.2020.64.6 | |
| Từ khóa | extranodal NK/T-cell lymphoma, nasal type, concurrent chemoradiotherapy, VIPD |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2020 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế